Biosyngen is excited to share that the U.S. Food and Drug Administration (FDA) has given the green light for its BRG01, an EBV-specific CAR-T cell therapy.

VISEN Pharmaceuticals reported that the Phase 3 PaTHway China Trial of Palopegteriparatide met its main and key secondary goals in treating adults with hypoparathyroidism.

Kyverna Therapeutics' KYV-101 Granted RMAT Designation by FDA for Progressive Myasthenia Gravis Treatment.

Initial Patient Administered in Phase 2 Study of New Anti-TIGIT Fc Fusion Protein with Serplulimab and HANBEITAI for First-line Therapy in Advanced Hepatocellular Carcinoma.

This research is assessing the administration of two doses of the ABRYSVO vaccine in immunocompromised adults aged 18.

Halda Therapeutics Raises $126M to Progress RIPTAC™ Cancer Treatments for Key Solid Tumors into Clinical Trials.

The FDA has given the green light to YORVIPATH® (Palopegteriparatide), marking it as the inaugural treatment option for adult hypoparathyroidism.

IASO Bio Gains U.S. FDA Clearance for Investigational New Drug Application of Equecabtagene Autoleucel for Two Additional Autoimmune Disorders.

Merck, via one of its subsidiaries, will acquire CN201, an innovative investigational bispecific antibody currently in the clinical trial phase for treating B-cell related disorders.

TG Therapeutics, has obtained clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) Application to study Azercabtagene Zapreleucel (azer-cel).

Angiex, has commenced patient dosing in their Phase 1 clinical trial of AGX101, an innovative TM4SF1-targeted Antibody-Drug Conjugate (ADC).

ARS Pharmaceuticals has recently achieved a milestone with the U.S. Food and Drug Administration (FDA) approval of neffy® (epinephrine nasal spray) 2 mg.